论文部分内容阅读
摘要目的(a)依照欧洲肝脏研究协会(EASL)标准和改良实体肿瘤疗效评价标准(mRECIST),评估化疗栓塞术对首次化疗栓塞术无反应的肝细胞癌(HCC)的疗效。(b)对初始无反应者与初始有反应者化疗栓塞术后的生存率进行比较。
Abstract Objectives (a) To evaluate the efficacy of chemoembolization in the treatment of non-responsive hepatocellular carcinoma (HCC) following chemoembolization in accordance with the European Association for the Study of the Liver (EASL) criteria and the mRECIST. (b) Comparison of survival after initial chemoembolization between initial responders and initial responders.